In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and ...

Before One UI 7, Samsung’s OS has always been a little hit or miss in some areas. I could never get fully invested in the ...

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes ...

Google's Pixel 9 Pro is one of the best smartphones out right now, and Amazon is offering a pretty good deal on it if you're looking to upgrade while also ...

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...